Skip to main content
Premium Trial:

Request an Annual Quote

Mylab, Hemex Health Partner to Develop POC Dx Tests

NEW YORK – Indian biotechnology company Mylab Discovery Solutions announced on Monday that it has partnered with Hemex Health to develop point-of-care diagnostic tests for COVID-19 and other diseases.

Under the technology agreement, Pune, India-based Mylab will develop assays and Hemex will provide its portable Gazelle POC testing platform and expertise, Mylab said in a statement.

The companies will use fluorescence immunoassays and electrophoresis-based diagnostics because they are "more sensitive than the normal rapid antigen tests and have fewer false negatives," according to Mylab. The tests will be jointly introduced internationally, including in the US, Europe, and Asia. 

The first product from the partnership is expected to launch in November.

Portland, Oregon-based Hemex currently distributes a point-of-care sickle cell test on its Gazelle Diagnostic Device in nine countries and a malaria test, while Mylab provides CoviSelf, a COVID-19 self-test kit, in India.

Financial and other terms of the agreement were not disclosed.